Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Positive topline data from phase II BRIGHT trial of Zygel in autism spectrum disorder

May 28, 2020

Zeposia receives European approval for the treatment of adult patients with RRMS

May 28, 2020

Researchers unveil PAR-1 as being involved in ALS pathogenesis

May 28, 2020

Merck & Co. identifies new Nav1.8 channel blockers

May 28, 2020

GPR139 receptor modulators discovered at BlackThorn Therapeutics

May 27, 2020

Atara Biotherapeutics presents phase I data on ATA-188 in patients with progressive MS

May 27, 2020

IL-10 upregulation with AD-110 improves cognition and stroke deficits in animal studies

May 27, 2020

Early roots of ALS visible in teeth

May 27, 2020

Phase III trial of efgartigimod in generalized myasthenia gravis meets primary endpoint

May 26, 2020

Merck & Co. identifies new LRRK2 inhibitors

May 26, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...